

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE III CLINICAL TRIAL OF SYS6043 FOR THE FIRST-LINE TREATMENT OF UNRESECTABLE RECURRENT OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER OFFICIALLY INITIATED IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Phase III clinical trial of SYS6043 (the “**Product**”) developed by the Group for the first-line treatment of unresectable recurrent or metastatic triple-negative breast cancer has been officially initiated at the first study centre in China.

The Product is a B7-H3-targeted antibody-drug conjugate (ADC) developed by the Group. Its antibody component can specifically bind to the surface of cells expressing B7-H3 and be internalised into the cells. Its linker-drug comprises a tetrapeptide linker conjugated to a topoisomerase I inhibitor, which can be specifically cleaved by proteases to release the small-molecule toxin to kill tumour cells, and exert a bystander effect to non-specifically kill neighbouring tumour tissue cells. Unlike antibodies utilising traditional wild-type fragment crystallisable (Fc) regions, the Product can reduce lymphocyte uptake and lower the risk of off-target toxicity, thereby improving treatment safety.

The clinical trial initiated is a randomised, open-label, multi-centre Phase III clinical trial, aiming to evaluate the clinical efficacy and safety of the Product compared to the investigator’s choice of chemotherapy as the first-line treatment in participants with unresectable recurrent or metastatic triple-

negative breast cancer. Currently, the recruitment and screening of participants for the Phase III clinical trial are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 22 October 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.